Table 2.
Cohort B: baseline characteristics and response to therapy
| Patient no. | Age | Stage of disease | Duration of first complete remission (mo) | Prior high-dose cytarabine | Prior autologous hematopoietic stem cell transplant | Bone marrow cytogenetics | No. cycles | Response |
|---|---|---|---|---|---|---|---|---|
| 2 | 60 | Relapse 3 | 2 | Yes | Yes | 46, XY, t(8;21) (q22;q22)/ t(1;5)(q32;q13) |
1 | Progressive disease |
| 5 | 39 | Relapse 5, refractory |
16 | Yes | Yes | 46,XX,t(8;21) (q22;q22),del(9) (q13q22) |
2 | Bone marrow blast clearance (from 68% to < 5%) after 1 cycle |
| 7 | 75 | Relapse 3 | 8 | No | No | 46,XX,t(4;21)(q31.3; q22)/46,XX |
3 | Bone marrow blast clearance (from 70% to < 5%) after 2 cycles |
| 17 | 25 | Relapse 1, refractory |
5 | Yes | Yes | 45,X,-X,t(8;21)(q22; q22)/46,XX |
1 | Progressive disease |
| 19 | 60 | Relapse 2 | 12 | Yes | No | 45X,-Yadd(1)(p36.3), t(8;21)(q22; q22) /46XY |
2 | > 50% decrease in marrow blasts (from 63% to 10%) after 1 cycle |
| 20 | 35 | Relapse 2 | 7 | Yes | Yes | 47,XY,+8,inv(16) (p13.1q22)/46XY |
2 | > 50% decrease (from 74% to 31%) in marrow blasts after 1 cycle |
| 21 | 51 | Relapse 1, refractory twice |
10 | Yes | No | 46,XX,add(7)(p22), t(8;21)(q22;q22); 47,idem,+der(21) t(8;21)(q22; q22)/46XX |
1 | > 50% decrease (from 76% to 27% blasts) in marrow blasts |
NOTE: HiDAC: high dose cytarabine. Auto HCT: autologous hematopoietic stem cell transplant. CR: complete remission.